On Friday, Cytokinetics Inc (NASDAQ: CYTK) was -8.19% drop from the session before settling in for the closing price of $54.70. A 52-week range for CYTK has been $30.68 – $110.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 12.30% over the past five years. When this article was written, the company’s average yearly earnings per share was at 2.37%. With a float of $113.59 million, this company’s outstanding shares have now reached $118.01 million.
Let’s look at the performance matrix of the company that is accounted for 423 employees. In terms of profitability, gross margin is -2872.48%, operating margin of -16297.79%, and the pretax margin is -17906.24%.
Cytokinetics Inc (CYTK) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cytokinetics Inc stocks. The insider ownership of Cytokinetics Inc is 3.33%, while institutional ownership is 113.26%. The most recent insider transaction that took place on Nov 12 ’24, was worth 370,880. In this transaction EVP Research & Development of this company sold 6,342 shares at a rate of $58.48, taking the stock ownership to the 113,878 shares. Before that another transaction happened on Nov 12 ’24, when Company’s Officer proposed sale 6,342 for $58.48, making the entire transaction worth $370,907.
Cytokinetics Inc (CYTK) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -1.38 earnings per share (EPS) during the time that was less than consensus figure (set at -0.95) by -0.43. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to -22.79% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
You can see what Cytokinetics Inc (CYTK) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 9.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1689.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.39, a number that is poised to hit -1.29 in the next quarter and is forecasted to reach -5.36 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Cytokinetics Inc (NASDAQ: CYTK) saw its 5-day average volume 1.47 million, a negative change from its year-to-date volume of 2.06 million. As of the previous 9 days, the stock’s Stochastic %D was 36.12%. Additionally, its Average True Range was 2.18.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 3.13%, which indicates a significant decrease from 3.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.09% in the past 14 days, which was higher than the 37.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $54.08, while its 200-day Moving Average is $60.13. Nevertheless, the first resistance level for the watch stands at $53.62 in the near term. At $57.02, the stock is likely to face the second major resistance level. The third major resistance level sits at $58.90. If the price goes on to break the first support level at $48.34, it is likely to go to the next support level at $46.46. Assuming the price breaks the second support level, the third support level stands at $43.06.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
There are 118,014K outstanding shares of the company, which has a market capitalization of 5.44 billion. As of now, sales total 7,530 K while income totals -526,240 K. Its latest quarter income was 460 K while its last quarter net income were -160,550 K.
